Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

Share Price is delayed by 15 minutes
Get Live Data
222.00    -5.00 (-2.20%)
Bid:
222.00
Ask:
232.00
Spread: 10.00 (4.505%)
Market Cap: £117.21m
APTD Live PriceLast checked at - London Stock Exchange

Intraday Aptitude Share Chart

Interim Management Statement

13 May 2013 07:00

RNS Number : 4884E
Microgen PLC
13 May 2013
 



microgen

www.microgen.com

 

13 May 2013

 

INTERIM MANAGEMENT STATEMENT

 

 

Microgen plc ('Microgen' or 'Group') provides its Interim Management Statement covering the period from 1 January 2013 to the date of this announcement. Microgen released its final results for the year ending 31 December 2012 on 25 February 2013.

 

There have been no significant changes since 1 January 2013 in the financial position of Microgen and its balance sheet remains strong. The Group had net cash at 30 April 2013 of £32.3 million (31 December 2012 : £32.1 million) before payment of the dividend and special dividend totalling £6.1 million, scheduled for 28 May 2013.

 

The Board remains satisfied with the financial performance of the Group with benefit continuing to be received from its conservative operational approach and annual licencing model. The Financial Systems Division has commenced delivery of a significant 5Series project with a large global bank and continues to perform satisfactorily. The Microgen Aptitude Solutions Division ("MASD") has started implementation of a major new financial services project in North America based on both Microgen Aptitude and Accounting Hub. In addition, MASD has further strengthened its intellectual property portfolio with three new patents being granted by the US Patent Office since 1 January 2013 in respect of the Microgen Aptitude technology.

 

Strategic Review

 

The Microgen Group continues to be financially very robust with a strong balance sheet and consistent profitability/cash flow. Following payment of the dividend and special dividend, through the Board's pro-active shareholder realisation programme, Microgen will have returned to shareholders 100% of the market capitalisation as at 13 October 2008 via dividends, special dividends, tender offers and share buy-backs.

 

The Microgen Aptitude technology and related applications (e.g. Microgen Accounting Hub) continue to be affirmed as being market leading. Originally targeted at the financial services sector, which remains the core of the business, Microgen Aptitude has also established a strong reputation in the digital media sector and is now developing opportunities in both the telecom and healthcare sectors.

 

The Financial Systems Division operates in more established product categories with high recurring revenues. The core business which operates within the financial services sector has been stable for a number of years and continues to provide predictable cash flows. Furthermore, the investment in the development of the 5Series Trust & Fund administration product and an increasingly active wealth management market, have resulted in a number of new customer wins during the past year as well as upgrades from the previous 4Series product version.

 

Notwithstanding these strengths and the success of the shareholder realisation programme since October 2008, Microgen is constrained as a result of being a small, independent public company. As a provider of enterprise solutions in a risk-averse market environment, the size of the group can be an inhibitor given the very large enterprise software companies with which MASD typically competes. As a result, the Board has determined this to be an appropriate time to evaluate the Group's future strategy to maximise the potential of Microgen's market-leading technology and applications and has therefore decided to undertake a strategic review of the Group.

 

Given the financial strength of Microgen, continuing with the current strategy and structure remains a viable option. Nevertheless, the strategic review will be wide-ranging and may, or may not, result in the disposal of one or both of the operating divisions. Alternatively, the Board will also consider the merits of acquisition(s) to increase the scale of the Group, including acquisition(s) which may or may not provide operating synergies with the current operating divisions. Investec Bank Plc has been appointed to assist the Board in the strategic review.

 

The Board anticipates that this process will take several months. Further announcements will be made as appropriate.

 

 

 

 

 

 

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

David Sherriff, Chief Executive Officer

Philip Wood, Group Finance Director

 

James Melville-Ross, FTI Consulting 020-7831-3113

Lucy Delaney, FTI Consulting

 

Rowena Murray, Investec Bank Plc 020-7597 5970

Andrew Pinder, Investec Bank Plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSAMMATMBABBTJ
Date   Source Headline
4th May 20218:55 amRNSTotal Voting Rights
29th Apr 20217:00 amRNSAppointment of Joint Broker
27th Apr 202111:28 amRNSResult of AGM
27th Apr 20217:00 amRNSAGM Statement
9th Apr 202111:14 amRNSHolding(s) in Company
29th Mar 20212:06 pmRNSBlock listing Interim Review
23rd Mar 202111:13 amRNSDirector/PDMR Shareholding
11th Mar 20214:44 pmRNSBlock Listing Application
2nd Mar 20217:00 amRNSNotice of Results
1st Mar 202112:36 pmRNSTotal Voting Rights
19th Jan 20217:00 amRNSTrading Update
6th Jan 20214:23 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSTotal Voting Rights
18th Dec 20209:13 amRNSHolding(s) in Company
1st Dec 202010:09 amRNSTotal Voting Rights
23rd Nov 20205:37 pmRNSHolding(s) in Company
28th Oct 20201:58 pmRNSDirector/PDMR Shareholding
29th Sep 20204:41 pmRNSSecond Price Monitoring Extn
29th Sep 20204:35 pmRNSPrice Monitoring Extension
28th Sep 202010:48 amRNSBlock listing Interim Review
9th Sep 20204:24 pmRNSGrant of awards under Performance Share Plan
2nd Sep 20201:38 pmRNSDirector Declaration
11th Aug 202012:19 pmRNSDirector/PDMR Shareholding
29th Jul 20207:00 amRNSInterim Results
6th Jul 20207:23 amRNSHolding(s) in Company
6th Jul 20207:21 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSTrading Update and Notice of Results
11th Jun 20204:41 pmRNSSecond Price Monitoring Extn
11th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20204:35 pmRNSPrice Monitoring Extension
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:35 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSTotal Voting Rights
29th Apr 202012:16 pmRNSDisclosure of Rights attached to Ordinary Shares
28th Apr 202012:45 pmRNSResult of AGM
21st Apr 20207:00 amRNSCOVID-19 Update and AGM Arrangements
8th Apr 20205:02 pmRNSDirector/PDMR Shareholding
8th Apr 20204:59 pmRNSDirector/PDMR Shareholding
27th Mar 202012:38 pmRNSBlock listing Interim Review
18th Mar 20205:00 pmRNSAnnual Report and Notice of AGM
16th Mar 20201:52 pmRNSBlock Listing Application
13th Mar 20205:11 pmRNSDirector/PDMR Shareholding
11th Mar 20207:00 amRNSAudited Preliminary Results
13th Feb 20205:26 pmRNSHolding(s) in Company
3rd Feb 20201:54 pmRNSTotal Voting Rights
22nd Jan 20202:44 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSTrading Update, Board Changes & Notice of Results
15th Jan 202012:01 pmRNSHolding(s) in Company
3rd Jan 202012:07 pmRNSSecond Price Monitoring Extn
3rd Jan 202012:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.